Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centrexion Therapeutics
This is a single site study. The study drug, 4975, will be administered in various dosing regimens by intra-articular injection followed by an observation period of up to 12 weeks. Pain in the treated knee will be assessed before, during and after administration of the study drug.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients aged 40 years or over.
Body mass index (BMI) of 35 or less.
History of OA of the knee for at least 1 year and has experienced pain in the target area for at least six months.
X-Ray of the target knee.
Willing and able to complete the study procedures.
You may not be if
Female patients who are pregnant or lactating or who plan to get pregnant.
Clinically significant form of joint disease other than OA.
Medical condition that could adversely impact the patient's participation, safety or affect the conduct of the study.
Prior major trauma in the target knee or major surgeries such as partial or total knee arthroplasty.
Arthroscopic surgery on the target knee within 6 months.
